Valbiotis 2024 financial results and future ambitions

French company Valbiotis has published its 2024 annual results, marking a strategic turning point with a turnover of €175,000, driven by direct sales of its new food supplements. Despite an increase in costs, the laboratory is maintaining its expansion strategy, driven by clinically validated products such as Valbiotis®PRO Cholesterol. Cash amounts to €11.6 million, with a long-term financing strategy in preparation.

For 2027, Valbiotis is targeting a turnover of €25 million, accompanied by a positive EBITDA in France. By 2030, the company aims to reach €100 million in turnover, with 30% internationally, and an EBITDA margin of 25 to 30%. Recent marketing extends to Valbiotis®PRO Metabolic Health, and TOTUM•854 is expected for the second quarter of 2025. Valbiotis remains focused on seeking international partnerships to strengthen its global presence.